India Cartridges Market By Preparation (Ready to use (RTU), Ready to sterilize (RTS), By Application (Small molecules, Biologics), By Material (Glass, Polymer), By End User (Hospitals & clinics, Pharma & biotech companies, Contract development and manufacturing organizations (CDMOs), Other), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Cartridges Market was valued at USD 66.13 Million in 2024 and is anticipated to reach USD 84.55 Million by 2030, with a CAGR of 4.14% during 2025-2030.

India's cartridges market is witnessing accelerated growth, fueled by the rapid expansion of the pharmaceutical industry and the surging demand for innovative drug delivery solutions. This momentum reflects a strategic shift toward safer and more efficient packaging systems, particularly for injectable medications. Advancements in material sciences, such as high-performance glass and specialized polymers, are driving the adoption of cutting-edge cartridge designs tailored for precision drug delivery.

Industry stakeholders are increasingly channeling investments into research and development to develop customized solutions that address stringent regulatory requirements and cater to the dynamic needs of healthcare providers and patients. This targeted approach underscores the sector's focus on enhancing functionality, safety, and compatibility with next-generation drug delivery devices, positioning India as a critical hub in the global pharmaceutical packaging market.8572

Key Market Drivers

Rising Prevalence of Chronic Diseases

Rising chronic diseases in India are increasing the need for efficient drug delivery systems such as pharmaceutical cartridges. Conditions such as diabetes, hypertension, and rheumatoid arthritis require long-term treatment, often through injectable medications that provide faster absorption and accurate dosing. Around 21% of India’s elderly population lives with at least one chronic disease, while hypertension and diabetes together represent about 68% of such conditions.

Cartridges play an important role in devices such as insulin pens, biologic injectors, and wearable drug delivery systems. These devices allow patients to administer medicines independently, improving treatment adherence and reducing dependence on hospitals. Self-injection devices have gained strong acceptance in urban and semi-urban areas, particularly for diabetes management.

Growth of biologic drugs and biosimilars has further increased cartridge demand. These sensitive formulations require sterile and precise packaging to maintain stability and dosage accuracy. As the elderly population expands and chronic disease treatment becomes more technology-driven, cartridges remain essential for reliable and patient-friendly drug delivery.

Advancements in Drug Delivery Technologies

Advances in drug delivery technologies are strengthening the role of cartridges in modern pharmaceutical systems. Devices such as auto-injectors, insulin pens, and wearable injectors rely on cartridges to store and deliver liquid medicines with high dosing accuracy. These technologies improve treatment convenience and reduce the risk of medication errors.

Self-injection systems have become more common for chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis. Pre-filled cartridges enable patients to manage therapy at home with minimal training. This shift supports healthcare access, particularly in remote regions where regular hospital visits remain difficult.

New materials and digital technologies are also improving cartridge performance. Borosilicate glass and medical-grade polymers enhance durability and chemical resistance, while connected devices track dosage and treatment adherence. These innovations are increasing demand for advanced cartridges compatible with smart drug delivery systems.

Growing Pharmaceutical Industry

Expansion of India’s pharmaceutical sector is another major factor supporting cartridge demand. The country hosts more than 262 US-FDA compliant manufacturing facilities and nearly 1,400 WHO-GMP approved plants, creating a strong foundation for large-scale drug production and advanced pharmaceutical packaging.

Growth in injectable drug manufacturing is particularly important for cartridges. Injectable therapies are widely used in oncology, chronic disease treatment, and emergency medicine because of their rapid therapeutic action. These drugs require sterile and precise packaging solutions, making cartridges a preferred option.

Pharmaceutical companies are also focusing on patient-centric delivery devices such as insulin pens and auto-injectors. These devices depend on cartridges to ensure safe storage, accurate dosing, and regulatory compliance. As India continues expanding its pharmaceutical production and biosimilar development capabilities, the role of cartridges in drug delivery systems will continue to grow.

Download Free Sample Report

Key Market Challenges

High Manufacturing and Material Costs

The production of high-quality cartridges involves substantial investments in advanced materials, precision engineering, and compliance with stringent regulatory standards. This cost-intensive process creates barriers for manufacturers, particularly smaller firms, limiting market growth.

Cartridges require specialized materials such as borosilicate glass or cyclic olefin polymers (COP) to ensure chemical resistance, sterility, and compatibility with sensitive drugs. These materials are expensive and often imported, adding to production costs. Setting up state-of-the-art manufacturing facilities capable of meeting international quality standards requires significant capital expenditure, which many domestic players find challenging. The high production costs are passed on to end-users, making advanced cartridges less accessible in price-sensitive markets, especially in rural areas or for small-scale pharmaceutical companies.

Regulatory and Quality Compliance Challenges

Cartridges, as an integral part of drug delivery systems, are subject to stringent regulatory requirements at both domestic and international levels. Meeting these standards poses a considerable challenge for manufacturers, affecting their ability to compete in global markets.

Compliance with global regulations such as ISO 11040-8 (for pre-fillable syringes and cartridges) and US FDA requirements demands meticulous quality control and documentation, which increases operational complexity and costs. Lengthy approval processes for new materials, designs, or drug-device combinations can delay time-to-market, affecting manufacturers' competitiveness. Inconsistent enforcement of quality standards within India creates uncertainty for manufacturers, deterring investment in advanced production facilities.

Key Market Trends

Adoption of Sustainable and Eco-Friendly Solutions

The push for sustainability in India’s pharmaceutical and healthcare sectors is accelerating innovation in the cartridges market, as tighter plastic packaging compliance and extended producer responsibility norms are pushing manufacturers to adopt recyclable materials, cleaner processing, and waste-reduction systems without compromising drug safety or quality. For instance, SCHOTT Poonawalla, positioned as India’s largest injectables-focused drug containment company, is strengthening the country’s cartridge ecosystem, while SCHOTT Pharma’s launch of ready-to-use 10 mL cartridges and polymer cartridge platforms with cleaner sterilization pathways highlights how leading suppliers are combining advanced drug delivery with lower-impact manufacturing. As sustainability becomes a stronger purchase criterion in regulated and export-oriented markets, companies that invest early in eco-friendly cartridge design and efficient production are likely to gain a sharper competitive edge in India.

Personalization and Precision in Drug Delivery Systems

The growing emphasis on personalized medicine and targeted drug delivery is increasing demand for highly customized cartridges in India, as drug makers design therapies around specific formulations, delivery devices, and patient needs rather than relying on one standard format. For instance, SCHOTT Poonawalla, described by its promoters as India’s largest injectables-focused drug containment solutions company, supplies cartridges for auto-injector pens and prefillable systems for biologics, while SCHOTT has also begun local production of high-precision syringe and cartridge glass tubing in Jambusar, Gujarat to serve rising demand for GLP-1 injectables such as semaglutide.

This patient-centric shift is also evident in next-generation self-injection platforms, with SCHOTT Pharma launching ready-to-use 10 mL cartridges for highly sensitive biologics and BD stating that its wearable injector platform can handle high-viscosity biologics up to 50 centipoise, enabling more convenient subcutaneous delivery outside hospital settings. In India’s diabetes care segment, Eris Lifesciences is expanding its Bhopal cartridge-filling facility by December 2025 and expects this to add 200 crore to 300 crore rupees in annual revenue to its insulin franchise, showing how major companies are investing in cartridge formats tailored for precision dosing, chronic therapy management, and home-based care.

Segmental Insights

Application Insights

Based on the category of Application, the Small Molecules segment emerged as the dominant in the India cartridges market in 2024. The small molecules segment continues to dominate the India cartridges market due to the extensive use of these drugs in a wide range of therapeutic areas, including oncology, cardiovascular diseases, diabetes, and infectious diseases. Small molecules typically require injectable delivery methods to ensure efficient drug absorption, and cartridges are crucial in ensuring the consistency and safety of such therapies.

India has a large population suffering from chronic conditions such as diabetes, hypertension, and arthritis. Many of these diseases are treated with small molecule injectables, increasing the demand for pre-filled cartridges for insulin pens, arthritis injectors, and other chronic care treatments. The Indian pharmaceutical industry is a global leader in the production of generic small molecules. With a growing focus on cost-effective drug delivery, pre-filled cartridges offer an affordable solution for administering these medications. Small molecules are often administered via injection for better bioavailability, especially in diseases like cancer and diabetes, where oral medications are less effective. Cartridges ensure precise dosing and ease of use, thus promoting patient adherence. These factors are expected to drive the growth of this segment.

Material Insights

The Glass Cartridges segment is projected to experience rapid growth during the forecast period. Glass cartridges have traditionally been the dominant choice in the India cartridges market, particularly in high-precision and high-value applications. Glass is preferred for its exceptional properties that ensure the safety, stability, and sterility of sensitive drug formulations, making it particularly valuable in the biologics segment.

Glass is highly inert, making it compatible with a wide range of drug formulations, particularly biologics and small molecules. It does not react with the drug, ensuring that the drug's chemical composition remains intact throughout its shelf life. Glass cartridges meet stringent global regulatory standards, including those set by the FDA, EMA, and WHO. They offer superior resistance to contamination and degradation, which is crucial for injectable drugs, especially biologics that are sensitive to temperature and light exposure. Glass is preferred in the pharmaceutical industry for its ability to maintain a high level of sterility. The material’s non-porous surface prevents bacterial growth, which is critical for preventing contamination during drug storage and administration. These factors collectively contribute to the growth of this segment.

Download Free Sample Report

Regional Insights

West India emerged as the dominant in the India Cartridges market in 2024, holding the largest market share in terms of value. The West region of India, which includes key states such as Maharashtra, Gujarat, and Rajasthan, plays a dominant role in the India cartridges market, primarily due to its well-established pharmaceutical manufacturing capabilities, advanced infrastructure, and robust export networks. These factors, coupled with the region's growing focus on innovation and research in the pharmaceutical and healthcare sectors, make it a central hub for the production and demand of cartridges used in drug delivery systems.

Maharashtra is home to some of India’s largest pharmaceutical companies, including Sun Pharma, Cipla, and Lupin. These companies are global leaders in the production of generic and branded drugs, including injectables, which heavily rely on cartridges for packaging and drug delivery. Mumbai, being the financial capital and a major port city, provides direct access to international markets. The demand for pharmaceutical products, including pre-filled cartridges for injectable drugs, is high due to Maharashtra's strong pharmaceutical export network, especially to North America, Europe, and emerging markets.

Recent Developments

• In February 2026, Dadachanji announced its entry into medical-device manufacturing in India, stating it would offer end-to-end capabilities across medical-device design, manufacturing, tooling, and consumables, which is relevant to domestic component and consumables production linked to cartridge-based platforms.
• In February 2026, Entero Healthcare Solutions completed its acquisition of a 51.5% stake in Anand Chemiceutics, a diagnostic and MedTech distributor serving more than 1,500 laboratories, hospitals, and government institutions, a move relevant to the broader cartridge-based diagnostics supply ecosystem in India.
• In December 2025, Cipla launched Afrezza in India, introducing an inhaled insulin product that uses single-use powder cartridges delivered through a dedicated inhaler.
• The US Food and Drug Administration (US FDA) conducted an unannounced inspection of Gland Pharma Ltd.’s Pashamylaram facility in Hyderabad from July 25 to August 2, 2024, to assess compliance with Good Manufacturing Practices (GMP). The inspection resulted in three Form 483 observations. Meanwhile, the company is actively developing new drug delivery systems, including pens and cartridges, as part of its commitment to providing high-quality injectable solutions at competitive prices.

Key Market Players

• Aptar Group,Inc.
• Baxter International, Inc
• Becton Dickinson India Private Limited
• Corning Incorporated
• Datwyler Pharma Packaging India Private Limited
• Gerresheimer AG
• Merck KGaA
• Nipro Medical India Pvt. Ltd.
• SCHOTT Glass India Pvt. Ltd
• Stevanato Group

Report Scope:

In this report, the India Cartridges Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Cartridges Market, By Preparation:

o   Ready to use (RTU)

o   Ready to sterilize (RTS)

• India Cartridges Market, By Application:

o   Small molecules

o   Biologics

• India Cartridges Market, By Material:

o   Glass

o   Polymer

• India Cartridges Market, By End User:

o   Hospitals & clinics

o   Pharma & biotech companies

o   Contract development and manufacturing organizations (CDMOs)

o   Other

• India Cartridges Market, By Region:

o   North India

o   East India

o   West India

o   South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Cartridges Market.

Available Customizations:

 India Cartridges market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).